FDA Approves Novel Alzheimer's disease Treatment through Traditional Pathway
The U.S. Food and Drug Administration (FDA) has converted Leqembi (lecanemab-irmb), a treatment for adult patients with Alzheimer's disease, to traditional approval. This decision was made after a confirmatory trial validated its clinical benefit. Leqembi is the first amyloid beta-directed antibody to transition from accelerated approval to traditional approval for treating Alzheimer's disease. The drug works by reducing the formation of amyloid plaques in the brain, a key characteristic of the disease. It was initially approved in January under the Accelerated Approval pathway, which allows the FDA to approve drugs for serious conditions with an unmet medical need based on surrogate endpoints. As part of the accelerated approval, the FDA required a confirmatory trial to verify the clinical benefit of Leqembi.
Leqembi's efficacy was evaluated in a Phase 3 randomized controlled clinical trial called Study 301 (CLARITY AD). The trial demonstrated its effectiveness in patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease.
Alzheimer's disease is a progressive brain disorder that affects millions of Americans, leading to memory loss, cognitive decline, and impaired daily functioning. The exact causes of Alzheimer's are not fully understood, but the disease is characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles in the brain, resulting in the loss of neurons and their connections.
It is important to note that patients treated with Leqembi who have the ApoE ε4 allele (homozygous) have a higher risk of developing amyloid-related imaging abnormalities (ARIA), including severe cases. The prescribing information recommends testing for ApoE ε4 status before starting Leqembi to assess the risk of ARIA.
Additionally, caution is advised when considering the use of Leqembi in patients taking anticoagulant medication, as it has been associated with an increased incidence of intracerebral hemorrhages compared to placebo.
Leqembi is contraindicated in patients with a serious hypersensitivity to lecanemab-irmb or any of its inactive ingredients. Adverse reactions may include angioedema (swelling) and anaphylaxis (allergic reaction).
The approved use of Leqembi is specifically for patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease, as this was the population studied in clinical trials. There is limited data regarding its safety and effectiveness in patients at earlier or later stages of the disease.
